XRAY

Business Context and Reporting Period

Company: DENTSPLY International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: The world's largest manufacturer of professional dental products, operating in over 120 countries. The company categorizes products into Dental Consumables, Dental Laboratory Products, and Dental Specialty Products (including implants and orthodontics).

Key Financial Metrics

Note: Debt figures derived from Balance Sheet (Notes payable + Long-term debt). Cash figures include Cash equivalents and Short-term investments.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 17.2% in Q2 and 17.9% YTD compared to 2007. Excluding precious metal content, sales grew 17.3% YTD, driven by 5.8% internal growth, 8.3% foreign currency translation, and 3.2% from acquisitions.
• Profitability: Net income rose 20.2% in Q2 and 18.5% YTD. The effective tax rate decreased to 28.5% (Q2) and 28.3% (YTD) from 31.6% and 30.8% in 2007, respectively, due to a lower German tax rate and entity restructuring benefits.
• Operating Expenses: SG&A expenses increased 16.7% in Q2 but remained stable as a percentage of sales (37.1% excluding precious metals). Restructuring costs decreased significantly to $1.5 million in Q2 from $3.2 million in the prior year.
• Interest Expense: Net interest expense turned from income in 2007 to an expense of $3.2 million in Q2 2008 due to diverging interest rates (lower USD vs. higher Euro/Swiss Franc) and currency fluctuations.
• Balance Sheet: Long-term debt increased by approximately $94.6 million YTD, while cash and short-term investments grew by over $100 million.

Guidance, Outlook, and Risks

• Internal Growth Outlook: Management maintains a long-term sustainable internal growth rate expectation of 4-6%. Q2 internal growth was 5.9% (excluding precious metals), with Europe leading at 10.2% and the U.S. at 0.9%.
• Capital Expenditures: Expected to be approximately $70 million to $75 million for the full year 2008.
• Stock Repurchases: The company purchased 2.4 million shares for $95.5 million in the first six months of 2008. Authorization remains for up to 17 million shares.
• Legal Proceedings:
  • Antitrust: Ongoing private class actions regarding tooth distribution practices (Trubyte teeth) and resale price maintenance claims.
  • Product Liability: Class action suits regarding Cavitron ultrasonic scalers (alleged misrepresentation of suitability for oral surgery and water sterility issues) in California and Pennsylvania/New Jersey.
• Market Risks: Significant exposure to foreign currency fluctuations (hedged via derivatives) and commodity price volatility (precious metals). The company notes that precious metal sales are largely pass-through costs with minimal impact on earnings.

Investor Verification Checklist

• Precious Metal Exposure: Verify the impact of precious metal price volatility on reported revenue vs. operating margin, as the company excludes this from internal growth metrics.
• Currency Hedging Effectiveness: Review Note 10 to assess the $243.3 million net fair value liability on derivatives and the impact of currency translation on net income.
• Legal Contingencies: Monitor the status of the antitrust resale price maintenance appeals and the Cavitron product liability class actions for potential settlement costs.
• Debt Structure: Confirm the terms of the new 12.6 billion Yen term loan (approx. $117.9 million) entered into July 2008 to refinance revolving credit.
• Working Capital Trends: Investigate the increase in days sales outstanding (DSO) to 56 days from 51 days at year-end 2007, which negatively impacted operating cash flow.